Product logins

Find logins to all Clarivate products below.


Rick Finch

Senior Vice President, Life Sciences and Healthcare

As Global Lead for Clarivate Life Sciences and Healthcare Consulting Services, Rick is responsible for trusted partnerships and customer success across all practice areas, including Discovery and Translational Sciences, Clinical and Regulatory, Market Access, New Product Planning, Commercial Strategy, HEOR and Technology Services.​

His focus is on helping executives improve decision making and accelerate execution in the areas of early stage scientific research, drug development, and commercialization. ​

Over the past 20+ years, Rick has worked with major pharmaceutical, digital advertising, high-tech, consumer goods and retail companies in areas such as product research and development, sales and marketing, operations, and information technology. During that time, he has led key transformation programs in analytics and data management, post-merger integration, product launch and support, new product development, digital sales and marketing, customer/patient centricity, and technology enablement.​

Prior to joining Clarivate in 2019, Rick was a Managing Director at Accenture, leading the sales and marketing consulting practice across Life Sciences, Consumer Goods and Retail. Rick has an M.Phil from the University of Oxford and a B.A. in History from Boston College.


arrow_forward
Get in touch with Rick

Related resources

应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径 应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径
Blog February 24, 2026
应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规
前进之路:收到 CRL 后该何去何从? 前进之路:收到 CRL 后该何去何从?
Blog February 24, 2026
前进之路:收到 CRL 后该何去何从?
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规
Relacorilant:当证据满足既定证据标准时 Relacorilant:当证据满足既定证据标准时
Blog February 24, 2026
Relacorilant:当证据满足既定证据标准时
FDA 临床试验 市场准入 最值得关注的药物 真实世界数据 美国市场 药政法规
Tolebrutinib:当安全性隐忧掩盖疗效信号 Tolebrutinib:当安全性隐忧掩盖疗效信号
Blog February 24, 2026
Tolebrutinib:当安全性隐忧掩盖疗效信号
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规 药物安全